

Please complete all sections of this form as thoroughly as possible. You may also include any additional clinical information pertinent to this authorization request.

<input type="checkbox"/> Initial treatment request	<input type="checkbox"/> Repeat course of treatment request	Date of request:
--	---	------------------

Member information		
Member name:	Date of birth:	Age:
Medicaid or member ID number:	Date of request:	
Member's DSM diagnoses:		

Provider information	
Requesting TMS clinician/facility:	NPI/TIN number:
Address:	
Phone:	Fax:
<input type="checkbox"/> In network <input type="checkbox"/> Out of network (please provide clinical rationale below)	

Initial treatment requirements
<input type="checkbox"/> Member is 18 years old or older and <input type="checkbox"/> Member is not pregnant or breastfeeding and <input type="checkbox"/> Member has a confirmed diagnosis of severe major depressive disorder, single or recurrent and <input type="checkbox"/> Resistance to prior treatment (one or more of the following) — please provide documentation of unsuccessful trials: <input type="checkbox"/> Inability to tolerate psychopharmacologic agents as evidenced by four trials of psychopharmacologic agents from at least two different agent classes, at or above the minimum effective dose and duration (at least one of which is in the antidepressant class), with distinct side effects; or <input type="checkbox"/> Inability to tolerate psychopharmacologic agents as evidenced by three different antidepressants from at least two different agent classes, plus one with an augmenting agent. Augmentation therapy is when one or more drugs is not an antidepressant but is added to increase the effect of an antidepressant drug for adults with major depressive disorder (e.g., adding Buspirone); or <input type="checkbox"/> Antidepressants contradicted, (e.g., medical condition or serious adverse effects) or <input type="checkbox"/> History of response to TMS in a previous depressive episode or <input type="checkbox"/> Currently receiving electroconvulsive therapy (ECT), and TMS is considered a less invasive treatment option or <input type="checkbox"/> Currently considering ECT, and TMS may be considered a less invasive treatment option

AND
<input type="checkbox"/> Trial of evidence-based psychotherapy known to be effective in the treatment of major depressive disorder without significant improvement in symptoms and documented as such by standardized rating scales that reliably measure depressive symptoms (GDS, PHQ-9, BDI, HAM-D, MADRS, QIDS, or IDS-SR);

AND there are no known potential contraindications — please mark if member has any of the below:
<input type="checkbox"/> Seizure disorder or any history of seizures (except those induced by ECT or isolated febrile seizures in infancy without subsequent treatment or recurrence) <input type="checkbox"/> Presence of acute or chronic psychotic symptoms <input type="checkbox"/> Known nonadherence with previous treatment for depression <input type="checkbox"/> Current or known substance use at time of referral or start of TMS treatments <input type="checkbox"/> Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of repetitive or severe head trauma, or primary or secondary tumors in the central nervous system <input type="checkbox"/> Presence of an implanted magnetic-sensitive medical device located less than or equal to 30 cm from the TMS magnetic coil or other implanted metal items including but not limited to a cochlear implant; implanted cardiac defibrillator (ICD); pacemaker; vagus nerve stimulation (VNS); or metal aneurysm clips or coils, staples, or stents



Repeat course of treatment requirements

Date of initial treatment, if known:

Member continues to meet the guidelines for initial course of treatment

AND

Member is experiencing continued depressive symptoms

AND

Member has responded to prior treatments as evidenced by a greater than 50% improvement in standardized rating scale measurements for depressive symptoms (note rating below);

GDS:	PHQ-9:	BDI:	HAM-D:	MADRS:	QIDS:	IDS-SR:
------	--------	------	--------	--------	-------	---------

Treatment plan requirements for both initial and retreatment (please choose requested number of units)

<input type="checkbox"/> 36 standard repetitive treatments	<input type="checkbox"/> 44 deep treatments
Once per day, five days per week, for six weeks	Once per day, five days per week, for four weeks
Six final sessions tapered over three weeks	24 final sessions with once per day, two days per week, for 12 weeks

Provider signature:

Date: